Bevacizumab,Durvalumab,Olaparib,Carboplatin,Paclitaxel
AstraZeneca,roche,Merck
['avastin', 'imfinzi', 'ovarian', 'brca', 'lynparza', 'astrazeneca']
imfinzi+lynparza+avastin+chemo gives astrazeneca hope however frail to gain a broader label in 1l ovarian cancer to cover patients without brca mutations #asco23 
Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.